Email
Print
Dermatological Diagnostics & Therapeutics Market - Forecast(2024 - 2030)
Dermatological Diagnostics & Therapeutics Market Overview
Dermatological Diagnostics & Therapeutics Market size is estimated to
reach $51.3 billion by 2027, growing at a CAGR of 8.5% during the forecast period
2022-2027. Dermatology is the field of medicine that includes the study,
diagnosis, and treatment of skin ailments. It also deals with the treatment of
conditions of the hair and nails. Typically, the diagnosis is carried out by
way of a visual examination, succeeded by microscopic observation of the skin
which assists in recognizing the ailment and establishing a treatment plan. In
order to carry out these procedures, dermatologists utilize a series of
diagnostic devices like imaging equipment, microscopes, and dermatoscopes. Dermatological
therapeutics include both clinical and surgical facets. Typically,
dermatologists favor minimally invasive therapeutic procedures for treating
skin ailments. Topical
corticosteroids serve an important role in the treatment of numerous
dermatologic conditions. They are FDA-approved and designated for the application
of inflammatory and pruritic presentations of dermatologic conditions. Retinoids are utilized
in the treatment of numerous different ailments and are efficient in the treatment
of numerous dermatological conditions like inflammatory skin ailments, skin
cancers like bexarotene for mycosis fungoides, and ailments of increased cell
turnover (for example, psoriasis), photoaging, and skin wrinkles. Immunosuppressants are
utilized to regulate serious manifestations of allergic, autoimmune, and
transplant-related ailments.
The increasing predominance of skin allergies, fungal infections, and skin cancer which may require the application of retinoids owing to pollution and alterations in the environment is set to drive the Dermatological Diagnostics & Therapeutics Market. The expanding population of the elderly aged 65 and above enduring skin ailments owing to reduction of elasticity and strength of the skin and decrease in the level of secretion is set to propel the growth of the Dermatological Diagnostics & Therapeutics Market during the forecast period 2022-2027. This represents the Dermatological Diagnostics & Therapeutics Industry Outlook.
Report Coverage
The report: “Dermatological Diagnostics & Therapeutics Market Forecast (2022-2027)”, by Industry ARC, covers
an in-depth analysis of the following segments of the Dermatological Diagnostics & Therapeutics Market.
Key Takeaways
- Geographically, North America Dermatological Diagnostics & Therapeutics Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027. The growth can be attributed to the surging healthcare spending, burgeoning awareness regarding skin ailments requiring the application of topical corticosteroids, and the powerful presence of pharmaceutical firms in the North American region.
- Dermatological Diagnostics & Therapeutics Market growth is being driven by the increasing burden of dermatology ailments which may require the application of topical corticosteroids, a rise in awareness levels of disease progression, and aetiology, and the expanding population of the elderly. However, the severe side effects of some classes of therapeutic medications are some of the major factors hampering the growth of Dermatological Diagnostics & Therapeutics Market.
- Dermatological Diagnostics & Therapeutics Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Dermatological Diagnostics & Therapeutics Market report.
Dermatological Diagnostics & Therapeutics Market Segment Analysis – By Product Type:
The Dermatological Diagnostics & Therapeutics Market based on product type can be further segmented into Dermatoscopes. Microscopes, Trichoscopes,
Imaging Equipment, Antibacterial Agents, Antifungal Agents, Antiviral Agents,
Corticosteroids, Retinoids, and Immunosuppressants. The Dermatoscopes Segment held the largest market share in 2021.
This growth is owing to the surging application of dermatoscopes in
Dermatological Diagnostics owing to the improved view of the skin offered by
dermatoscopes to physicians that can assist in the diagnosis of skin conditions
like melanoma. The proliferating application of dermatoscopes in diagnosis of scabies
is further propelling the growth of the Dermatoscopes segment.
Furthermore, the Corticosteroids segment is estimated to grow with the
fastest CAGR of 9.4% during the forecast period 2022-2027 owing to the heightening
application of topical corticosteroids which are the most typically prescribed agents in the treatment of
dermatologic conditions.
Dermatological
Diagnostics & Therapeutics Market Segment Analysis – By Application:
The Dermatological Diagnostics & Therapeutics Market based on application can be further
segmented into Alopecia, Herpes, Psoriasis, Rosacea,
Atopic Dermatitis, and Others.
The Psoriasis Segment
held the largest market share in 2021. This
growth is owing to the increasing count of cases pertaining to plaque
psoriasis brought about by misguided T-cell attacks on the skin. Dermatoscopes
are typically utilized in Dermatological Diagnostics. The novel product launches directed the attention of market players in extending
their market for dermatology therapeutics, and collaborations and acquisitions are
further propelling the growth of this segment.
Furthermore, the Atopic Dermatitis segment is
estimated to grow with the fastest CAGR of 9.6% during the forecast period 2022-2027 owing to the increasing
burden of allergic reactions attributed principally to food allergies and rising environmental
pollution with the most typical treatment being the application of topical
corticosteroids in combination with aggressive moisturizing.
Dermatological Diagnostics & Therapeutics Market Segment Analysis – By Geography:
The Dermatological Diagnostics & Therapeutics Market based on geography can be further segmented
into North America, Europe, Asia-Pacific, South America, and Rest of the World. North
America (Dermatological Diagnostics & Therapeutics Market) held the largest
share with 35% of the overall market in 2021. The growth of this region is
owing to the surging awareness regarding skin
ailments in the North American region. Dermatoscopes, microscopes, and imaging equipment are typically
utilized in Dermatological Diagnostics. The superior access to healthcare and
the supportive reimbursement policies are further propelling the growth of the Dermatological Diagnostics & Therapeutics Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the expanding population of the elderly enduring skin ailments in the Asia-Pacific region. The proliferating ever-increasing unfulfilled medical requirements in the developing nations and the rising cases of skin ailments in children which may require the application of topical corticosteroids are further fuelling the progress of the Dermatological Diagnostics & Therapeutics Market in the Asia-Pacific region.
Dermatological Diagnostics & Therapeutics Market Drivers
Surging Applications Of Dermatoscopes Are Projected To Drive The Growth Of Dermatological Diagnostics & Therapeutics Market:
Dermoscopy, also termed dermatoscopy, epiluminescence microscopy, or skin surface microscopy is a non-invasive, in-vivo technique that has conventionally been useful for the assessment of suspicious skin lesions. It can assist in recognizing lesions and differentiating melanocytic lesions from dysplastic lesions, melanomas, or non-melanoma skin cancers like basal cell carcinoma or squamous cell carcinoma. Furthermore, over the past numerous years, the application of dermoscopy has extended to involve use for the diagnosis of dermatological ailments inclusive of inflammatory dermatosis, pigmentary dermatosis, infectious dermatosis, and disorders of the hair, scalp, and nails. As per Dermengine findings show that dermoscopy diagnoses are up to 35% more accurate than clinical diagnoses without the application of a dermatoscope. Definitely, this is a percentage that has a measurable difference in patient health outcomes together with the early detection of severe skin conditions. Further, research goes on to show that practicing dermatoscopy permits professionals to be able to detect 92% of melanomas instantly. Dermatoscopes functionally simulate a magnifying lens, with the additional characteristics of much higher magnification, and an adjustable inbuilt illuminating system. A hand lens, even with in-built illumination, cannot permit visualization beyond the surface of the skin owing to the reflection and scattering of light from the stratum corneum. Dermatoscopes can evaluate structures to the depth of the reticular dermis, and report images for future comparison. The basic principle of dermoscopy is transillumination of a lesion in order to investigate it with high magnification to visualize subtle characteristics. Light incident on a surface such as the skin can be reflected, refracted, diffracted, and/or absorbed. The physical characteristics of the skin influence these phenomena. The most novel generation of dermatoscopes involves inbuilt crossed-polarizers, which filter out scattered light from the periphery, reduce glare, and permit visualization of substratal structures without the requirement of a linkage fluid. The surging applications of dermatoscopes are therefore fuelling the growth of the Dermatological Diagnostics & Therapeutics Market during the forecast period 2022-2027.
Heightening Applications Of Topical Corticosteroids In Dermatology Are Expected To Boost The Growth Of The Dermatological Diagnostics & Therapeutics Market:
Topical corticosteroids have become imperative in the treatment of different dermatoses. Hydrocortisone was the earliest compound. Alterations in the basic structure produced in vivo activity and thus distinct topically active compounds were discovered. Apart from the Stoughton vasoconstrictor assay, numerous other techniques are utilized for potency evaluation of topical corticosteroids. Topical corticosteroids are restricted based on the potency and action of these molecules. The well-recognized indications are for ailments like psoriasis, restricted areas of vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, lichen planus, lichen simplex chronicus, discoid lupus erythematosus, and lichen sclerosis. They are efficient for conditions involving hyper-proliferation, immunological, and inflammatory characteristics. As per the Indian Journal of Dermatology, Venereology and Leprology (IJDVL), it has been recommended that superpotent topical corticosteroids like clobetasol and halobetasol propionate not be utilized for a duration of more than 14 days with the total dose not surpassing 50 gms per week for halobetasol and 60 gms per week for clobetasol. The heightening applications of topical corticosteroids in dermatology are therefore driving the growth of the Dermatological Diagnostics & Therapeutics Market during the forecast period 2022-2027.
Dermatological Diagnostics & Therapeutics Market Challenges
Challenges Of Dermatological Diagnostics & Therapeutics Are Hampering The Growth Of The Dermatological Diagnostics & Therapeutics Market:
While the Infra-red (IR) spectrum has been found to be advantageous for dermatological diagnostic uses, the basic disadvantage of IR imaging is the finite depth of penetration, normally confined to 2-3 mm. For skin affected by hypertrophic scarring, sclerosis, or scabs resulting from wounds, this shallow range presents a challenge. Presently, up to 70% of patients develop hypertrophic scars succeeding burns. Deitch and colleagues discovered that burn wounds healing within 3 weeks had a reduced risk of hypertrophic scarring, while wounds taking more than 3 weeks had a soaring risk for developing a pathologic, hypertrophic scar. A more current investigation of greater than 500 pediatric scald burn patients verified the time to healing as a powerful predictor of hypertrophic scarring, with 21 to 25 days recognized as the critical time frame. Furthermore, native fluorophores like oxygenated hemoglobin, which absorbs IR, further influence the imaging range unfavorably. Additionally, while the IR imaging methods offer insight into the structural details of the skin; the dearth of cellular and molecular-level specificity restricts the application of these methods for preliminary diagnosis of skin ailments. Further tests are still essential for an in-depth, all-inclusive assessment of ailment symptoms. Patient safety can be jeopardized when using or taking dermatologic therapy owing to medical error, patient noncompliance, unfavorable impacts, or medication interactions. It is thus of utmost significance to reduce, and if possible avert these hazards. These issues are thus hampering the growth of the Dermatological Diagnostics & Therapeutics Market.
Dermatological Diagnostics & Therapeutics Industry Outlook:
Product launches, mergers and acquisitions, partnerships and collaborations are key strategies adopted by players in the Dermatological Diagnostics & Therapeutics Market. Key companies of this market are:
- AGI Dermatics
- Allergan Inc
- Amgen Inc,
- Chester Valley Pharmaceuticals Inc.
- Dermik Laboratories Inc.
- Eisai Inc.
- Ferndale Laboratories Inc.
- Genentech Inc.
- Medicis Pharmaceutical Corp
- Onset Therapeutics
Recent Developments
- In September 2021, Zelira Therapeutics (ZLD) introduced its earliest product line, RAF FIVE, by way of its dermatology subsidiary, Ilera Derm LLC. The RAF FIVE product line includes the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick-Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, Clear the Way Acne Treatment Pads and After Hours Moisturising Lotion Acne Treatment. These products are recognized to involve skin-boosting constituents like glycerin, hyaluronic acid, peptides, thiotaine, and niacinamide.
- In April 2021, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), declared the introduction of SkinMedica® Neck Correct Cream, the earliest product from the professional-grade skin care line formulated to attend to the particular biology of the skin on the neck and décolleté area. SkinMedica® Neck Correct Cream was planned to avert the early signs as well as treat the visible appearance of moderate to serious neck aging. It is clinically proven to firm and tighten the look of creepy skin, avert and decrease the look of sagging, smooth deep lines and wrinkles, and improve skin tone evenness.
- In October 2020, DermBiont, Inc., a clinical-stage precision dermatology firm spotting skin ailments at their root cause has extended its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. SeylanMED’s lead drug candidate, a topical AKT inhibitor gel, has the possibility to be the earliest patient-applied treatment for seborrheic keratosis. Seborrheic keratosis (SKs) are benign clonal tumors with activating mutations in the RTK-P13K, Akt, mTOR signaling pathways.
Related Reports
Report Code: HCR 89649
Report Code: HCR 35129
Report Code: HCR 23828
For more Lifesciences and Healthcare Market reports, please click here